GeneDx Holdings (WGS) shares nosedived 23.06% in pre-market trading on Wednesday, despite reporting better-than-expected first-quarter revenue. The sharp decline suggests investors may be focusing on other aspects of the company's financial performance and outlook.
The genetic testing company announced Q1 2025 revenue of $87.1 million, surpassing the IBES estimate of $79.5 million. However, GeneDx reported a net loss of $6.5 million for the quarter. While the company highlighted an adjusted net income of $7.7 million, the significant difference between GAAP and non-GAAP figures might be raising concerns among investors about the company's path to sustainable profitability.
GeneDx also provided full-year revenue guidance of $360 to $375 million, which appears to be in line with or slightly above the current consensus view of $358.9 million. However, the lack of a clear profitability outlook in the provided information may be contributing to investor unease. The substantial pre-market drop indicates that market participants may be reassessing the company's valuation in light of its current financial position and future prospects, despite the revenue growth.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.